Celldex Therapeutics (CLDX) has been on a downward spiral lately with significant selling pressure. After declining 17.4% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...

Celldex Therapeutics (CLDX) closed the last trading session at $40.49, gaining 5.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $69.57 indicates a 71.8% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $20.30. While the lowest estimate of $27 indicates a 33.3% decline from the current price level, the most optimistic analy ...

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET. A live webcast of the panel discussion will be available on the investor section of the Celldex website. A replay of the webcast will be ava ...

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an "Inflammation & Immunology Corporate Panel Discussion" at TD Cowen's 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET. A live webcast of the panel discussion will be available on the investor section of the Celldex website. A replay of the webcast will be ava ...

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Cell ...

Celldex Therapeutics (CLDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Sinc ...

Celldex Therapeutics (CLDX) closed the last trading session at $51.37, gaining 45.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $65 indicates a 26.5% upside potential.The average comprises seven short-term price targets ranging from a low of $27 to a high of $80, with a standard deviation of $18.18. While the lowest estimate indicates a decline of 47.4% from the current price ...

HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock are being offered by the Company. The final terms of the ...

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.67 per share when it actually produced a loss of $0.81, delivering a surprise of -20.90%.Over the last four quarters, the ...

Core Insights - Celldex Therapeutics has made significant advancements in the development of barzolvolimab, particularly in treating mast cell-mediated diseases, with positive data reported from various clinical studies [2][4]. Clinical Development - Phase 3 studies for chronic spontaneous urticaria (CSU) are expected to begin in summer 2024, following positive Phase 2 data [1][4]. - The Phase 2 CSU study reported a statistically significant mean change in the weekly urticaria activity score (UAS7) at 12 weeks, demonstrating the drug's efficacy [4][5]. - Enrollment is nearing completion for the Phase 2 chronic inducible urticaria (CIndU) study, with data anticipated in the second half of 2024 [1][5]. - A Phase 2 study for prurigo nodularis (PN) is set to start in early 2024, building on positive Phase 1 data [1][6]. Financial Performance - As of December 31, 2023, the company reported cash, cash equivalents, and marketable securities totaling $423.6 million, a significant increase from $235.3 million at the end of Q3 2023 [8]. - Total revenue for Q4 2023 was $4.1 million, up from $1.6 million in Q4 2022, driven by increased services under manufacturing and research agreements [9]. - Research and development expenses rose to $30.4 million in Q4 2023, compared to $22.9 million in Q4 2022, primarily due to barzolvolimab clinical trials [9][10]. - The net loss for Q4 2023 was $43.3 million, or ($0.83) per share, compared to a net loss of $26.5 million, or ($0.56) per share, in Q4 2022 [12]. Pipeline and Future Plans - Celldex is expanding its barzolvolimab program into additional mast cell-mediated diseases and plans to introduce a bispecific antibody for inflammatory diseases [2][3]. - The company is also conducting a Phase 2 study in eosinophilic esophagitis (EoE), with protocol amendments to optimize dosing [6].